Q2 Holdings reports Q2 revenue up 13%, raises 2026 guidance

Attovia Therapeutics Inc., an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US initial public offering.

TORONTO, July 29, 2026 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”), a wholly-owned subsidiary of Sprott Inc. (“Sprott”) (NYSE/TSX: SII), on behalf of the Sprott Physical Copper Trust (NYSE: SCOP) (TSX: COP.UN) (TSX: COP.U) (the “Trust”), a closed-end